HTT
HTT Informations sur la molécule
| Nom anglais | Huntingtin | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 10 | Alias de la cible | Huntingtin，HD protein，HD，HTT，Huntington Disease Protein，IT15，Huntingtin (Huntington Disease)，LOMARS，Huntingtin Protein |
| Phase de R&D la plus avancée | Phase 3 Clinical | ||
| Nom anglais | Huntingtin |
| Alias de la cible | Huntingtin，HD protein，HD，HTT，Huntington Disease Protein，IT15，Huntingtin (Huntington Disease)，LOMARS，Huntingtin Protein |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 10 |
| Phase de R&D la plus avancée | Phase 3 Clinical |
HTT Liste de produits
- Attribut
Protein (1)
- Bibliothèque de produits
En ligne (1)
- Espèces
Human (1)
- Étiquette
His Tag & MBP Tag (1)
- Marqueur
Unconjugated (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
 Human | E. coli | Human HTT Protein, MBP,His Tag (MALS verified) |  |  |  Ajouter au panier |
Quantité totale1
- 1
HTTContexte de la molécule
Huntingtin is the protein coded for by the HTT gene. Autosomal dominant mutation in the Huntingtin (Htt) protein is the cause of Huntington’s Disease (HD). In HD, the polyglutamine (polyQ) domain in the N-terminal sequenceof the protein is expanded beyond a threshold of 36 glutamines. mutant polyQ expansion strongly correlates in an inverse manner to disease age of onset.
HTTAlias de la molécule
HTT,Htt,Huntingtin
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Tominersen | RG-6042; RO-7234292; ISIS-443139 | Phase 3 Clinical | Ionis Pharmaceuticals Inc | Huntington Disease | Details |
| SKY-0515 | SKY-0515 | Phase 3 Clinical | Skyhawk Therapeutics Inc | Huntington Disease; Nervous System Diseases | Details |
| Votoplam | PTC-518; PTC518 | Phase 3 Clinical | Ptc Therapeutics Inc | Huntington Disease | Details |
| WVE-003 | WVE-003 | Phase 2 Clinical | Wave Life Sciences Ltd | Huntington Disease | Details |
| NA-841 | NA-841; NA841 | Phase 2 Clinical | Biomed Industries Inc | Huntington Disease | Details |
| SPK-10001 | SPK-10001; RG-6662; HTT miRNA GT | Phase 2 Clinical | Spark Therapeutics Inc | Huntington Disease | Details |
| ER-2001 | ER-2001; ER2001 | Phase 2 Clinical | Shenzhen Aima Biotechnology Co Ltd | Huntington Disease | Details |
| ARO-HTT | ARO-HTT; SRP-1005 | Phase 1 Clinical | Arrowhead Pharmaceuticals Inc | Huntington Disease | Details |
| ALN-HTT-02 | ALN-HTT-02; ALN-HTT02 | Phase 1 Clinical | Alnylam Pharmaceuticals Inc | Huntington Disease | Details |
| PTC-607 | PTC-607 | Phase 1 Clinical | Ptc Therapeutics Inc | Huntington Disease | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques